CD15/FUT4 overexpression is driven by constitutive oncogenic signalling pathways in the tumor cells (innate immune resistance) acting as a novel RAF-MEK-ERK kinase downstream regulator through ERBB3 or FGFR4 activation, respectively. Here, ERBB3 is linked to neoplasm.